Shore Capital is pleased to have acted as Financial Adviser, Nominated Adviser and Joint Broker on Amryt Pharma’s acquisition of Aegerion Pharmaceuticals, a US based biopharmaceutical company focused on rare and orphan diseases with operations in the US, Europe and certain countries in Latin America, an $8.0 million interim placing at 90p per share, a $60.0 million equity raise (applying a pre-money equity valuation of Amryt of $96 million), certain other matters pursuant to the acquisition and the admission of the enlarged issued share capital of Amryt to trading on AIM and Euronext Growth.
The transaction remains subject to, inter alia, the approval of shareholders at Amryt’s General Meeting on 19 September 2019.
For further information please contact:
+44 (0) 20 7408 4090
Research: Tara Raveendran
For Shore Capital media enquiries, please contact:
Adele Gilbert: +44 (0)79 6622 4514
Note to editor
About Shore Capital
We are an independent securities business offering institutional and corporate clients leading investment banking, research, sales and trading services, including fixed income. We are represented across the UK enabling extensive distribution and institutional coverage. This distribution capability is complemented by our experienced corporate advisory and broking team who offer discreet, innovative and valued advice to companies on both the Main Market and AIM. Shore Capital is also the 3rd largest market maker by number of AIM stocks covered.
Our cross-disciplinary team has deep, market leading experience in a wide range of small and mid-cap UK companies within the following sectors: Consumer, Financials, Healthcare, Insurance, Natural Resources, Real Estate, Support Services, Technology and Media. Our research on over 250 companies is distributed to an extensive institutional client base in the UK and Europe.
Shore Capital is a trading name of both Shore Capital Stockbrokers Limited and Shore Capital and Corporate Limited.